{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T20:24:52Z","timestamp":1791491092244,"version":"4.3.4"},"reference-count":44,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.clinthera.2023.07.007","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T16:07:18Z","timestamp":1690474038000},"page":"1029-1033","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Seeing Colchicine in a New Light: Repurposing Low-dose Colchicine for Secondary Prevention of Cardiovascular Disease"],"prefix":"10.1016","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2226-538X","authenticated-orcid":false,"given":"Stefan Mark","family":"Nidorf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.07.007_bib0001","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/s41569-021-00668-4","article-title":"Therapeutic strategies targeting inflammation and immunity in atherosclerosis: how to proceed?","volume":"19","author":"Engelen","year":"2022","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0002","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0003","unstructured":"O\u2019Riordan M Hopes fade for a CV indication for canakinumab: what\u2019s next for the inflammatory hypothesis? TCTMD; February 1, 2019. https:\/\/www.tctmd.com\/news\/hopes-fade-cv-indication-canakinumab-whats-next-inflammatory-hypothesis."},{"key":"10.1016\/j.clinthera.2023.07.007_bib0004","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.15896","article-title":"Colchicine: an ancient drug with novel applications","volume":"178","author":"Dasgeb","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0005","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM198604173141601","article-title":"Colchicine in the prevention and treatment of the amyloidosis of familial Mediterranean fever","volume":"314","author":"Zemer","year":"1986","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0006","series-title":"A Short History of the Gout and the Rheumatic Diseases","author":"Copeman","year":"1964"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0007","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1161\/01.CIR.97.21.2183","article-title":"Colchicine treatment for recurrent pericarditis. A decade of experience","volume":"97","author":"Adler","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0008","first-page":"710","article-title":"Colchicine disposition in patients with familial Mediterranean fever with renal impairment","volume":"21","author":"Ben-Chetrit","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0009","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3899\/jrheum.111533","article-title":"Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout","volume":"39","author":"Crittenden","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0010","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1136\/annrheumdis-2015-207984","article-title":"Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims","volume":"75","author":"Solomon","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0011","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1161\/CIRCULATIONAHA.119.045256","article-title":"From CANTOS to CIRT to COLCOT to Clinic. Will all atherosclerosis patients soon be treated with combination lipid-lowering and inflammation-inhibiting agents?","volume":"141","author":"Ridker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0012","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.semarthrit.2015.06.013","article-title":"Colchicine\u2014update on mechanisms of action and therapeutic uses","volume":"45","author":"Leung","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0013","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1439-0272.1986.tb01801.x","article-title":"The effects of long-term colchicine therapy on male fertility in patients with familial Mediterranean fever","volume":"18","author":"Ehrenfeld","year":"1986","journal-title":"Andrologia"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0014","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0015","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1093\/eurheartj\/ehab221","article-title":"Colchicine and the heart","volume":"42","author":"Imazio","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keab303","article-title":"Comparative efficacy of low-dose versus regular-dose colchicine to prevent flares in gout patients initiated on urate-lowering therapies","author":"Ahn","year":"2021","journal-title":"Rheumatology"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0017","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/00498254.2021.1909782","article-title":"Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens","volume":"51","author":"Karatza","year":"2021","journal-title":"Xenobiotica"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0018","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/clpt.1993.161","article-title":"Colchicine disposition in human leukocytes after single and multiple oral administration","volume":"54","author":"Chappey","year":"1993","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0019","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2125.1994.tb04328.x","article-title":"Colchicine concentration in leukocytes of patients with familial Mediterranean fever","volume":"38","author":"Chappey","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0020","doi-asserted-by":"crossref","first-page":"e16580","DOI":"10.1097\/MD.0000000000016580","article-title":"Clinical outcomes after colchicine overdose: a case report","volume":"98","author":"Fu","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2023.07.007_bib0021","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.2337\/dcS13-2038","article-title":"Intolerance to statins: mechanisms and management","volume":"36","author":"Bitzur","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0022","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.amjcard.2006.10.039","article-title":"Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease","volume":"99","author":"Nidorf","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0023","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0024","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2023.07.007_bib0025","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0026","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1093\/eurheartj\/ehab115","article-title":"Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials","volume":"42","author":"Fiolet","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0027","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0028","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0029","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0030","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.arcmed.2015.01.004","article-title":"Colchicine reduces restenosis after balloon angioplasty treatment for in-stent restenosis","volume":"46","author":"Kong","year":"2015","journal-title":"Arch Med Res"},{"issue":"6 Suppl 102","key":"10.1016\/j.clinthera.2023.07.007_bib0031","first-page":"S136","article-title":"Effect of colchicine on serum lipid levels","volume":"34","author":"Ugurlu","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0032","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s13023-019-1201-7","article-title":"Update on the management of colchicine resistant familial Mediterranean fever (FMF)","volume":"14","author":"El Hasbani","year":"2019","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0033","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s40261-022-01209-8","article-title":"The effect of years-long exposure to low-dose colchicine on renal and liver function and blood creatine kinase levels: safety insights from the Low-Dose Colchicine 2 (LoDoCo2) Trial","volume":"42","author":"van Broekhoven","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0034","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s40264-022-01265-1","article-title":"Colchicine drug interaction errors and misunderstandings: recommendations for improved evidence-based management","volume":"46","author":"Hansten","year":"2023","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152150","article-title":"Systematic review of colchicine neuromyopathy: risk factors, duration and resolution","volume":"58","author":"McEwan","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0036","first-page":"400","article-title":"Examining the characteristics of colchicine-induced myelosuppression in clinical cases: a systematic review","volume":"50","author":"Sim","year":"2023","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijcard.2022.12.026","article-title":"Drivers of mortality in patients with chronic coronary disease in the Low-Dose Colchicine 2 trial","volume":"372","author":"Opstal","year":"2023","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0038","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s11739-021-02654-7","article-title":"Colchicine efficacy and safety for the treatment of cardiovascular diseases","volume":"16","author":"Andreis","year":"2021","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0039","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/2396987320972566","article-title":"Colchicine for prevention of vascular inflammation in Non-CardioEmbolic stroke (CONVINCE)\u2014study protocol for a randomised controlled trial","volume":"6","author":"Kelly","year":"2021","journal-title":"Eur Stroke J"},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2023.07.007_bib0040","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0735-1097(22)01566-2","article-title":"Synergy-everolimus eluting stent with a bioabsorbable polymer in ST elevation myocardial infarction- clear SYNERGY OASIS-9 trial","volume":"79","author":"Jolly","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0041","first-page":"99","volume":"92","author":"Ponte-Negretti","year":"2022","journal-title":"Arch Cardiol Mex"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0042","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0043","first-page":"4","article-title":"2023 Guidelines of the Taiwan Society of Cardiology on the diagnosis and management of chronic coronary syndrome","volume":"39","author":"Ueng","year":"2023","journal-title":"Acta Cardiol Sin"},{"key":"10.1016\/j.clinthera.2023.07.007_bib0044","unstructured":"FDA OKs Low-Dose Colchicine for Broad CV Indication (medscape.com)."}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002576?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823002576?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:59:30Z","timestamp":1758963570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823002576"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0149291823002576"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.007","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Seeing Colchicine in a New Light: Repurposing Low-dose Colchicine for Secondary Prevention of Cardiovascular Disease","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}